Aza-podophyllotoxin derivative

Show results for

Proteomics (2)
Unknown (1)

Organisms

Andropogon gerardi (2)
Bacteria (2)
Canis lupus familiaris (2)
Cnidaria (2)
Cricetulus griseus (2)
Eukaryota (2)
Fasciola (2)
Hepatitis B virus (2)
Human betaherpesvirus 5 (2)
Madurella mycetomatis (2)
Mesocricetus auratus (2)
Miscanthus x giganteus (2)
Mus musculus (2)
Mycobacterium tuberculosis (2)
Orthoflavivirus (2)
Panicum virgatum (2)
Platyhelminthes (2)
Pseudomonas aeruginosa AES-1R (2)
Rattus norvegicus (2)
Rattus rattus (2)
Saccharomyces cerevisiae (2)
Schizosaccharomyces pombe (2)
Severe acute respiratory syndrome coronavirus 2 (2)
Shigella (2)
Sorghastrum nutans (2)
Streptococcus dysgalactiae subsp. equisimilis SK1249 (2)
Streptococcus pneumoniae (2)
Streptomyces coelicolor A3(2) (2)
Toxoplasma gondii (2)
Tripsacum dactyloides (2)

Repository

pride (2)

Tissue

Breast cancer cell line (1)
Cell culture (1)

Disease

Breast cancer (2)

Technology Type

Mass Spectrometry (2)
Bottom-up proteomics (1)
Data-dependent acquisition (1)
Shotgun proteomics (1)

Publication Date

2025 (1)
2020 (1)

Release Date

2021 (1)

Lab affiliation

Department of Radiology Stanford School of Medicine Stanford University (1)
Stanford University, Canary Center at Stanford for Cancer Early Detection, USA (1)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

Novel Aza-Podophyllotoxin Derivative in Triple Negative Breast Cancer

Four cell lines (MCF10A, MCF12A, MDA-MB-231, and MDA-MB-468) were treated with a novel drug candidate.

ORGANISM(S): Homo sapiens (Human)

2020-11-09 | PXD018929 | Pride

Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.

Not available

S-EPMC7851402 | biostudies-literature

Non-allosteric Inhibition of Enolase 1 Impedes Growth of Triple-Negative Breast Cancer

1. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated for 6h with DMSO or SU212 and incubated at different temperatures and protein differences in the soluble fractions were determined. 2. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and BT549 cells were treated with DMSO (vehi...